Community-based ways to boost RSV vaccine use in Latino adults
Part of Infections clinical trials.
This study looks at community-based ways to help Latino adults ages 50 and older in San Francisco and Daly City get the RSV vaccine. The goal is to learn what works best to increase vaccination rates.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years or older
- You identify as Latino, Latina, Latinx, or as part of an indigenous group from Latin America
- You have not yet received the RSV vaccine
- You live or work in San Francisco or Daly City and plan to stay for the next year
- You speak English or Spanish and have a cell phone
- You are not living in a nursing home and no one in your household is already in this study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether connecting with friends and health workers can help more Latino people in Maryland get vaccinated or boosted against COVID-19. It aims to reach both those who are already vaccinated and those who are hesitant.
This trial tests a program to help community health centers recommend and boost HPV vaccination rates among Latino adolescents aged 11-12. It aims to support health care providers and staff with education and resources.
This trial tests a new RSV vaccine in adults aged 60 and older to see if it is safe and helps the immune system fight RSV. If you are generally healthy or have stable medical conditions without recent infections or vaccines, you may be eligible.
This study looks at how to increase preventive care—especially flu and pneumonia vaccines—in people age 70 and older. It may help you get up to date on vaccines that can lower the risk of serious infections.
This study tests an RSV vaccine in adults aged 18 and older, especially those with chronic health issues like heart or lung disease. It aims to see how safe and effective the vaccine is at preventing RSV infections.
This trial tests a booster dose of an experimental RSV vaccine (SCB-1019T) in healthy adults aged 60-85 who have already received the approved RSV vaccine AREXVY. The goal is to see if the booster is safe and boosts your immune system.
Hear when a new Social Networks trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.